Nektar Therapeutics
NKTR
112 hedge funds and large institutions have $198M invested in Nektar Therapeutics in 2025 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 33 increasing their positions, 37 reducing their positions, and 77 closing their positions.
10% less call options, than puts
Call options by funds: $32.1M | Put options by funds: $35.6M
4.83% less ownership
Funds ownership: 66.55% → 61.72% (-4.8%)
11% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 37
14% less capital inflows, than outflows
Capital inflows: $30.1M | Capital outflows: $35.2M
29% less funds holding
Funds holding: 158 → 112 (-46)
58% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 77
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.57M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.7M |
| 3 |
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.14M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.08M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.1M |
| 2 |
Eventide Asset Management
Boston,
Massachusetts
|
-$4.52M |
| 3 |
Almitas Capital
Santa Monica,
California
|
-$3.14M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.88M |
| 5 |
Exome Asset Management
New York
|
-$1.67M |
NKTR Hedge Fund Activity: Q2 2025 in Review
112 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2025, worth a combined $198M — up 135% from $84.2M a quarter earlier.
Sellers outnumbered buyers: 77 funds closed out of NKTR and 32 opened new positions — a net loss of 45 holders — while 37 trimmed existing stakes and 33 added.
The largest buyer was Millennium Management, adding an estimated $5.57M. The largest seller was BlackRock, cutting an estimated $7.1M.
- 112 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2025, down from 158 in Q1 2025.
- Funds reported $198M of Nektar Therapeutics stock for Q2 2025, up 135% quarter-over-quarter.
- 32 funds opened new Nektar Therapeutics positions in Q2 2025 and 77 closed out, a net change of -45 holders.
- The largest Nektar Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $5.57M added.
- The largest Nektar Therapeutics seller in Q2 2025 was BlackRock, an estimated $7.1M sold.
Based on aggregated 13F filings for Q2 2025.